🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

50 results for “Istituto” Clear

  1. Augmentin Fruit, 400 mg/57 mg/5 ml suukaudse suspensiooni pulber

    Istituto Gentili S.r.l.

    Urinary Tract Infections

    phase 3 small molecule active

    1 trial

  2. GLASDEGIB , DAUNORUBICIN , AZACITIDINE , AMSACRINE , CYTARABINE , DECITABINE , FLUDARABINE , ETOPOSIDE , GILTERITINIB, IDARUBICIN , VENETOCLAX , MITOXANTRONE , IVOSIDENIB , CYTARABINE , CLADRIBINE , GEMTUZUMAB OZOGAMICIN

    Istituto Gentili S.r.l.

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  3. Intrarosa 6.5 mg pessary

    Istituto Gentili S.r.l.

    Postmenopausal women with previous breast cancer or currently under anti-oesterogenic therapy (aromatase inhibitor +/- LHRH analogue) presenting vulvar, vaginal or urinary bothersome symptoms (genitourinary syndrome).

    phase 3 small molecule active

    1 trial

  4. PLACEBO, Nicetile 500 mg polvere per soluzione orale

    Istituto Gentili S.r.l.

    amyotrophic lateral sclerosis

    phase 3 small molecule active

    1 trial

  5. Placebo is solution for injection (150 mg/ml) contained in vials equal to those of Canakinumab and appears identical to the Test product. Placebo is provided by Novartis pharma., Ilaris 150 mg/ml solution for injection

    Istituto Gentili S.r.l.

    PAPA syndrome

    phase 3 small molecule active

    1 trial

  6. Sugammadex 100 mg/ml solution for injection, Rocuronium bromide 10 mg/ml solution for injection/infusion

    Istituto Gentili S.r.l.

    patients scheduled to undergo elective surgical procedures with general anesthesia

    phase 3 small molecule active

    1 trial

  7. Veltassa 8.4 g powder for oral suspension, Placebo

    Istituto Gentili S.r.l.

    End Stage Kidney Disease on chronic dialysis therapy

    phase 3 small molecule active

    1 trial

  8. Wegovy 2.4 mg solution for injection in pre-filled pen, Rybelsus 14 mg tablets, Clopidogrel Medreg 75 mg filmom obalené tablety, Wegovy 0.25 mg solution for injection in pre-filled pen, Wegovy 0.5 mg solution for injection in pre-filled pen, Wegovy 1 mg solution for injection in pre-filled pen, Rybelsus 7 mg tablets, Wegovy 1.7 mg solution for injection in pre-filled pen, Acetylsalicylic acid Krka 100 mg enterotabletter, Rybelsus 3 mg tablets

    Istituto Gentili S.r.l.

    Diabetes Mellitus, Cardiovascular disease, Overweight (BMI ≥27 kg/m²), Obesity (BMI≥30kg/m2)

    phase 3 small molecule active

    1 trial

  9. 177Lu-PSMA I&T_IRSTIRCCS

    Istituto Gentili S.r.l.

    PSMA PET/CT positive advanced/metastatic tumours

    phase 2 small molecule active

    1 trial

  10. 177Lu-PSMA I&T_IRSTIRCCS

    Istituto Gentili S.r.l.

    Oligometastatic prostate carcinoma

    phase 2 small molecule active

    1 trial

  11. 68Ga-FAPI-46

    Istituto Gentili S.r.l.

    oncological disease suspicion/ new diagnosis or with a previously treated tumour, with an inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT

    phase 2 small molecule active

    1 trial

  12. 68Ga-FAPI-46 PET-CT for molecular assessment of fibroblast activation and risk assessment in solid tumors (FAPI Basket)

    Istituto Gentili S.r.l.

    Solid tumors

    phase 2 other active

    1 trial

  13. AMINOHIPPURIC ACID, OMNIPAQUE 300 mg I/ml soluzione iniettabile, Felzartamab

    Istituto Gentili S.r.l.

    Membranous nephropathy

    phase 2 small molecule active

    1 trial

  14. Argon/Oxygen mixture, OXYGEN

    Istituto Gentili S.r.l.

    Cardiac arrest

    phase 2 small molecule active

    1 trial

  15. BEVACIZUMAB, DC-VACCINE_IRSTIRCCS, Lonsurf 20 mg/8.19 mg film-coated tablets, VEGZELMA 25 mg/mL concentrate for solution for infusion, VEGZELMA 25 mg/mL concentrate for solution for infusion, Lonsurf 15 mg/6.14 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion, BEVACIZUMAB

    Istituto Gentili S.r.l.

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  16. BLEOPRIM 15 mg polvere per soluzione iniettabile, Carboplatino AHCL 10 mg/ml Concentrato per soluzione per infusione

    Istituto Gentili S.r.l.

    relapsing vulvar carcinoma already subjected to multiple treatments

    phase 2 small molecule active

    1 trial

  17. CYCLOPHOSPHAMIDE MONOHYDRATE, VINORELBINE, Tecentriq 840 mg concentrate for solution for infusion

    Istituto Gentili S.r.l.

    Inoperable locally advanced or metastatic TNBC patients, previously treated with anti-PD-L1/PD1- regimens

    phase 2 small molecule active

    1 trial

  18. DC-VACCINE_IRSTIRCCS, Proleukin 18 x 106 UI Polvere per soluzione iniettabile o per infusione

    Istituto Gentili S.r.l.

    Stage IV colorectal cancer

    phase 2 small molecule active

    1 trial

  19. DURVALUMAB, Ceralasertib

    Istituto Gentili S.r.l.

    Stage III NSCLC patients with loco-regional relapse > 12 months from the end of CRT +/- < 3 metastatic lesions after PACIFIC regimen or PACIFIC-like regimens (concurrent or sequential chemo-radiotherapy followed by maintenance durvalumab), regardless of PD-L1 status, but without EGFR, HER-2 or MET exon14 skipping mutations, ALK, ROS1, RET or NTRK rearrangements.

    phase 2 small molecule active

    1 trial

  20. EstroTep 500 MBq/mL, solution injectable, ELACESTRANT, EXEMESTANE, ELACESTRANT

    Istituto Gentili S.r.l.

    Metastatic hormone receptor-positive/HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  21. Fycompa 4 mg film-coated tablets, Fycompa 2 mg film-coated tablets

    Istituto Gentili S.r.l.

    White-Sutton syndrome (POGZ-Related Disorder)

    phase 2 small molecule active

    1 trial

  22. Gazyvaro 1,000 mg concentrate for solution for infusion., OMNIPAQUE 300 mg I/ml soluzione iniettabile

    Istituto Gentili S.r.l.

    Idiopathic Nephrotic Syndrome

    phase 2 small molecule active

    1 trial

  23. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan Baxter 50 mg Compresse rivestite

    Istituto Gentili S.r.l.

    Locally recurrent, inoperable, and/or metastatic inflammatory breast cancer with lymphangitic spread to the chest wall

    phase 2 small molecule active

    1 trial

  24. KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED , CISPLATIN , CARBOPLATIN

    Istituto Gentili S.r.l.

    Malignant Pleural Mesothelioma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources